UY30833A1 - Nanoemulsion - Google Patents

Nanoemulsion

Info

Publication number
UY30833A1
UY30833A1 UY30833A UY30833A UY30833A1 UY 30833 A1 UY30833 A1 UY 30833A1 UY 30833 A UY30833 A UY 30833A UY 30833 A UY30833 A UY 30833A UY 30833 A1 UY30833 A1 UY 30833A1
Authority
UY
Uruguay
Prior art keywords
nanoemulsion
diseases
refers
composition
active agent
Prior art date
Application number
UY30833A
Other languages
English (en)
Inventor
Montserrat Foguet Roca
Original Assignee
Biofrontera Bioscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38042639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30833(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biofrontera Bioscience Gmbh filed Critical Biofrontera Bioscience Gmbh
Publication of UY30833A1 publication Critical patent/UY30833A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invencion se refiere a una nanoemulsion comprendiendo por lo menos un componente acuoso y un vehículo, el que comprende un componente lipofilo y un tensioactivo y por lo menos un alcohol. Se refiere además a una composicion comprendiendo dicha nanoemulsion y un agente activo.La composicion está presente como un gel y el agente activo es ácido 5-aminolovulínico, un derivado, precursor y/o metabolito del mismo. Se refiere además a la preparacion de dicha nanoemulsion y a su uso para el tratamiento de enfermedades dermatologicas, enfermedades asociadas con virus, también enfermedades asociadas con proliferacion celular, y enfermedades tumorales y/o psoriasis.
UY30833A 2006-12-22 2007-12-21 Nanoemulsion UY30833A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026698A EP1938801A1 (en) 2006-12-22 2006-12-22 Nanoemulsion

Publications (1)

Publication Number Publication Date
UY30833A1 true UY30833A1 (es) 2008-07-31

Family

ID=38042639

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30833A UY30833A1 (es) 2006-12-22 2007-12-21 Nanoemulsion

Country Status (18)

Country Link
US (2) US11540981B2 (es)
EP (2) EP1938801A1 (es)
JP (1) JP5558827B2 (es)
CN (1) CN101588792B (es)
AR (1) AR064659A1 (es)
AU (1) AU2007338323B2 (es)
BR (1) BRPI0720853A2 (es)
CA (1) CA2670715C (es)
CL (1) CL2007003730A1 (es)
ES (1) ES2602107T3 (es)
IL (1) IL198934A (es)
MX (1) MX2009006088A (es)
NZ (1) NZ577061A (es)
RU (1) RU2491917C2 (es)
UA (1) UA101471C2 (es)
UY (1) UY30833A1 (es)
WO (1) WO2008077641A1 (es)
ZA (1) ZA200903468B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
CN107080703A (zh) 2006-12-01 2017-08-22 安特里奥公司 肽纳米粒子和其用途
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
CA2688415C (en) 2007-05-31 2015-11-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
JP2010143848A (ja) * 2008-12-18 2010-07-01 Kao Corp 化粧料
CN101874795A (zh) * 2009-04-28 2010-11-03 上海复旦张江生物医药股份有限公司 5-氨基酮戊酸在制备治疗hpv病毒感染的药物的用途
KR20120129864A (ko) 2009-08-21 2012-11-28 타겟티드 딜리버리 테크놀러지스 리미티드 소포성 제형
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
DE202010004750U1 (de) * 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
EP2585046A4 (en) * 2010-06-23 2013-11-06 Brightside Innovations Inc LECITHINTRÄGERVESIKEL AND METHOD FOR THE PRODUCTION THEREOF
BRPI1002486B1 (pt) 2010-07-22 2017-07-18 Evidence Soluções Farmacêuticas Ltda Epp Stabilized topical composition and process of obtaining composition stable topic
JP2012051823A (ja) * 2010-08-31 2012-03-15 Fujifilm Corp 難容性薬物含有水中油型乳化組成物及びその製造方法
US9012502B2 (en) 2010-09-14 2015-04-21 Sbi Pharmaceuticals Co., Ltd. Cancer heat therapy-enhancing agent
US8992994B2 (en) 2010-10-21 2015-03-31 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
US9789123B2 (en) * 2010-10-21 2017-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
AU2011340797B2 (en) * 2010-12-10 2017-08-10 Ns Technologies Pty Ltd Methods for forming miniemulsions and use thereof for delivering bioactive agents
CN103270168A (zh) 2010-12-24 2013-08-28 爱科来株式会社 癌细胞的检测方法
DE102010056192A1 (de) 2010-12-28 2012-06-28 Gabriele Blume Kolloidales Trägersystem mit penetrierenden Eigenschaften zum Einschließen lipophiler Wirkstoffe und Öle für die topische Anwendung
SG10201804552WA (en) * 2011-01-24 2018-07-30 Anterios Inc Nanoparticle compositions, formulations thereof, and uses therefor
WO2012103035A1 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Nanoparticle compositions
FR2977801B1 (fr) * 2011-07-11 2013-08-16 Fabre Pierre Dermo Cosmetique Dispositif et procede pour la sterilisation a ultra-haute temperature d'une emulsion, notamment dermo-cosmetique, instable a la temperature de sterilisation
EP2804587B1 (en) 2012-01-19 2019-05-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Formulation and method for increasing oral bioavailability of drugs
CN102600178A (zh) * 2012-03-08 2012-07-25 西北农林科技大学 一种复方盐酸布替萘芬纳米乳及其制备方法
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CA2871821C (en) 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
JP6112498B2 (ja) * 2012-07-20 2017-04-12 株式会社 Ｍ Ｌａｂｓ 防腐剤・界面活性剤フリーの化粧品原料液、化粧品及び化粧品原料液の調製法
US10137085B2 (en) 2014-03-19 2018-11-27 Nano And Advanced Materials Institute Limited Nanoemulsion for transdermal delivery and method of making the same
WO2015155703A2 (en) 2014-04-09 2015-10-15 Nanoceutica Laboratories Pvt. Ltd Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
WO2016128858A1 (en) * 2015-02-11 2016-08-18 Towhidi Armin Extender for cryopreservation of bovine sperm
WO2016182926A1 (en) * 2015-05-08 2016-11-17 Affinsci Inc. Preparation of nanoemulsions
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
HUE059066T2 (hu) 2015-05-21 2022-10-28 Dermavant Sciences GmbH Topikus gyógyszerkészítmények
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
ES2860807T3 (es) 2015-10-15 2021-10-05 Dusa Pharmaceuticals Inc Iluminador ajustable para terapia y diagnóstico fotodinámicos
GB201522398D0 (en) * 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
CN105997875B (zh) * 2016-07-19 2019-05-21 重庆医科大学 一种明显提高难溶性药物生物利用度的油包水型纳米乳及其制备方法
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
BR112019010131A2 (pt) 2016-11-21 2019-10-08 Eirion Therapeutics Inc entrega transdérmica de agentes grandes
JP7454492B2 (ja) * 2017-07-17 2024-03-22 デューサ ファーマシューティカルズ インコーポレイテッド 皮膚障害に対する光線力学的治療方法
CN107233303A (zh) * 2017-08-07 2017-10-10 苏州纳美特生物科技有限公司 一种氨基酮戊酸冷霜及其制备方法和应用
TWI719263B (zh) * 2017-10-27 2021-02-21 財團法人國家衛生研究院 用於鼻黏膜之奈米級乳液免疫載劑及其製備方法
US10959975B1 (en) * 2017-11-02 2021-03-30 The Tetra Corporation Antifungal composition, method of making composition, and method of using composition
US10357567B1 (en) * 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
AU2019266360A1 (en) * 2018-05-11 2021-01-07 Formulytica Pty Ltd Sub-micron emulsions
EP3583954A1 (en) * 2018-06-19 2019-12-25 neubourg skin care GmbH Nanodispersions of birch bark extract, electrospun fibers containing such nanodispersions and their use for the treatment of wounds
JP7231741B2 (ja) * 2018-08-23 2023-03-01 マルホ株式会社 異波長の２つの光の曝露を含む光線力学療法
AU2019332696A1 (en) * 2018-08-31 2021-03-18 Kemin Industries, Inc. Technology for water dispersible phospholipids and lysophospholipids
CN113260257B (zh) * 2018-12-28 2022-09-06 南京善思生物科技有限公司 纳米农药制剂及其制备方法
CN110169990A (zh) * 2019-06-19 2019-08-27 苏普丘昆基蒂 牛至油治疗猪腹泻自乳化配方产品及制造工艺
CN114081851A (zh) * 2021-11-01 2022-02-25 苏州纳美特生物科技有限公司 保湿喷雾
WO2024208433A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol
AU2024253808A1 (en) * 2023-04-06 2025-10-09 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol
WO2024208434A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Pressurized nanoemulsion
AU2024249973A1 (en) * 2023-04-06 2025-10-09 Biofrontera Bioscience Gmbh Nanoemulsion formulation with improved tacrolimus stability and skin penetration

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
NZ260307A (en) * 1993-04-14 1995-03-28 Colgate Palmolive Co Microemulsion cleaning solution comprising an anionic organic surfactant and a cosurfactant
JPH08175986A (ja) * 1994-09-20 1996-07-09 Johnson & Johnson Medical Inc 経皮活性を示す５−アミノレブリン酸含有薬学組成物
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
SE9503143D0 (sv) 1995-09-12 1995-09-12 Astra Ab New preparation
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5895786A (en) 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
ES2187612T3 (es) 1996-09-16 2003-06-16 Nestle Sa Microemulsion comestible para recubrir productos alimenticios y su uso para tostar y convertirlos en crujientes en un microondas.
PT842606E (pt) * 1996-11-13 2000-08-31 Manuel Gomes Moniz Pereira Microemulsoes de desinfeccao
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
US6620437B2 (en) * 1998-07-30 2003-09-16 Colgate-Palmolive Co. Water-in-oil microemulsion for providing cosmetic attributes to fabric softening base composition
DE19852245A1 (de) * 1998-11-12 2000-05-18 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Nanoemulsion
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) * 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2795960B1 (fr) * 1999-07-05 2001-10-19 Sanofi Elf Microemulsions stables pour l'administration d'acides gras a l'homme ou a l'animal, et utilisation de ces microemulsions
US7919113B2 (en) * 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
DE10003620A1 (de) * 2000-01-28 2001-08-02 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US6823387B1 (en) * 2000-06-23 2004-11-23 Microsoft Corporation System and method for enhancing a server's ability to withstand a “SYN flood” denial of service attack
ATE463237T1 (de) 2000-08-16 2010-04-15 Gen Hospital Corp Topische aminolevulinsäure-photodynamische therapie für akne vulgaris
JP2002302414A (ja) 2000-12-26 2002-10-18 Kokuriyuudou:Kk スフィンゴ脂質構造物質含有乳化組成物及びその製造方法
US7314624B2 (en) * 2001-06-05 2008-01-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2003030926A1 (en) * 2001-10-05 2003-04-17 Procyte Corporation Stable solutions of peptide copper complexes and cosmetic and pharmaceutical formulations produced therefrom
US20030167033A1 (en) 2002-01-23 2003-09-04 James Chen Systems and methods for photodynamic therapy
JP2006505583A (ja) * 2002-10-25 2006-02-16 フォーミックス エルティーディー． 化粧剤および医薬用フォーム
DE602004007184T2 (de) * 2003-04-17 2008-02-28 Affectis Pharmaceuticals Ag Mittel und Verfahren zur Diagnose und Behandlung affektiver Störungen
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
AU2004273779B2 (en) 2003-06-04 2009-10-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
EP1598060A1 (en) * 2004-05-18 2005-11-23 Nestec S.A. Oil-in-water emulsion for delivery
FR2872038A1 (fr) * 2004-06-23 2005-12-30 Rhodia Chimie Sa Composition cosmetique comprenant un polyorganosiloxane et ses utilisations
TWI365075B (en) * 2004-09-22 2012-06-01 Kao Corp Microemulsion
EP1655021B1 (en) * 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
JP4444149B2 (ja) * 2005-03-30 2010-03-31 株式会社ナリス化粧品 超微細エマルジョンで構成される皮膚外用剤
KR100929264B1 (ko) * 2005-04-28 2009-12-01 에스비아이 아라프로모 가부시키가이샤 피부외용제
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion

Also Published As

Publication number Publication date
UA101471C2 (en) 2013-04-10
CN101588792B (zh) 2012-03-21
US11540981B2 (en) 2023-01-03
EP2120872A1 (en) 2009-11-25
MX2009006088A (es) 2009-08-28
ZA200903468B (en) 2010-02-24
US20090324727A1 (en) 2009-12-31
IL198934A (en) 2016-04-21
CA2670715C (en) 2015-11-24
US20230201087A1 (en) 2023-06-29
WO2008077641A1 (en) 2008-07-03
CA2670715A1 (en) 2008-07-03
IL198934A0 (en) 2010-02-17
AR064659A1 (es) 2009-04-15
EP1938801A1 (en) 2008-07-02
AU2007338323B2 (en) 2013-07-11
JP5558827B2 (ja) 2014-07-23
CL2007003730A1 (es) 2009-01-23
EP2120872B1 (en) 2016-09-21
BRPI0720853A2 (pt) 2014-03-25
AU2007338323A1 (en) 2008-07-03
NZ577061A (en) 2012-01-12
JP2010513363A (ja) 2010-04-30
RU2009128179A (ru) 2011-01-27
RU2491917C2 (ru) 2013-09-10
CN101588792A (zh) 2009-11-25
ES2602107T3 (es) 2017-02-17

Similar Documents

Publication Publication Date Title
UY30833A1 (es) Nanoemulsion
CL2013002550A1 (es) Una formulacion farmaceutica inyectable subcutanea liquida estable altamente concentrada de un anticuerpo anti-her2 farmaceuticamente activo que consiste esencialmente de trastuzumab; his/hci un agente estabilizador y un surfactante no ionico; kit y su uso para tratar enfermedades tales como cancer (divisional de solicitud n°0269-2012).
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
CU23821A3 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
MX2015005328A (es) Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas.
PE20150200A1 (es) Formulacion de anticuerpos
CO6720961A2 (es) Imidazopiridazinas sustituidas
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
CL2008001756A1 (es) Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac)
CL2011000774A1 (es) Formulacion farmaceutica que comprende el compuesto 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluorobencil]-2h-ftalazin-1-ona en dispersion solida con un polimero de matriz; correspondiente a copovidona, util en el tratamiento del cancer.
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
PE20151425A1 (es) Formulaciones farmaceuticas muy concentradas que comprenden un anticuerpo anti-cd20
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CR11472A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CO6670568A2 (es) Métodos de terapia combinada para tratar enfermedades profilerativas
BR112014017650A8 (pt) Uso de ésteres de forbol para tratar ou prevenir um ou mais dos sintomas da doença de parkinson
UY32970A (es) Acidos 3-fenilpropionicos sustituidos y su uso
UY32502A (es) Agentes antihelmínticos y su utilización
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
BRPI0920973B8 (pt) composição aquosa contendo hormônio estimulanete de folículos
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CL2013001935A1 (es) Formulacion ácida acuosa que comprende un primer péptido enlazado a fluorocarburo; metodo para obtener dicha formulación; uso de dicha formulación para tratar o prevenir infeccion patógena, una enfermedad autoinmunitaria o cancer.
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190117